Brought to you by 
Protein Design Labs, Roche sign deal for Zenapax; deal ends
27 Nov 2006
Executive Summary
Protein Design Labs (develops humanized monoclonal antibodies) and Roche signed a worldwide co-development and commercialization agreement for Zenapax (daclizumab), a Phase II humanized monoclonal antibody for moderate to severe asthma.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Terminated
Deal Type
-
Alliance
- Co-Promotion
- Includes Contract
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Protein Design Labs, Roche sign deal for Zenapax; deal ends
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice